Codexis and Matrix Laboratories enter into partnership for development and commercialization of novel process

17-Jun-2005

Codexis announced it has signed an agreement with Matrix Laboratories (Matrix), a leading provider of active pharmaceutical ingredients (APIs) to the global pharmaceutical industry, for the development and commercialization of the API for a high-value pharmaceutical product.

Codexis will employ its proprietary pharmaceutical process re-engineering technology platform to develop a novel synthetic process for the product via a Codexis Thoroughbred(TM) biocatalyst. The process will be transferred to Matrix for scale-up and manufacturing. Under the terms of the collaboration, Codexis will receive research and development funding, milestone payments and a royalty on net sales of the product. Matrix will receive exclusive manufacturing and marketing rights to the novel process. Further financial terms were not disclosed.

Other news from the department business & finance

These products might interest you

Pharmaceutical Substances

Pharmaceutical Substances by Thieme Verlag

Look up Industrial Syntheses of 2,600 APIs

Your tool for Syntheses, Patents and Applications – Pharmaceutical Substances

technical literature
AZURA Purifier + LH 2.1

AZURA Purifier + LH 2.1 by KNAUER

Preparative Liquid Chromatography - New platform for more throughput

Save time and improve reproducibility during purification

LC systems
Loading...

More news from our other portals

All FT-IR spectrometer manufacturers at a glance